Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of “Buy” from Analysts

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have been assigned an average recommendation of “Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $30.50.

A number of equities research analysts have weighed in on TYRA shares. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Tuesday, February 18th. UBS Group initiated coverage on Tyra Biosciences in a report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price objective for the company.

Tyra Biosciences Stock Performance

Tyra Biosciences stock opened at $9.66 on Friday. The company has a market capitalization of $488.82 million, a PE ratio of -6.00 and a beta of 1.09. The company has a 50 day moving average price of $12.59 and a 200-day moving average price of $16.45. Tyra Biosciences has a fifty-two week low of $9.49 and a fifty-two week high of $29.60.

Insider Buying and Selling at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 7,779 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $16.29, for a total transaction of $126,719.91. Following the completion of the transaction, the director now owns 447,857 shares in the company, valued at $7,295,590.53. The trade was a 1.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last 90 days, insiders have sold 21,998 shares of company stock valued at $344,818. 15.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tyra Biosciences

Several institutional investors have recently bought and sold shares of TYRA. KLP Kapitalforvaltning AS purchased a new stake in shares of Tyra Biosciences during the fourth quarter worth about $31,000. US Bancorp DE purchased a new stake in Tyra Biosciences during the 4th quarter worth approximately $50,000. BNP Paribas Financial Markets acquired a new position in Tyra Biosciences during the 4th quarter valued at approximately $60,000. Aquatic Capital Management LLC purchased a new position in shares of Tyra Biosciences in the fourth quarter worth $64,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Tyra Biosciences by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock worth $132,000 after buying an additional 3,236 shares during the period. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.